Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neumora Therapeutics, Inc. (NMRA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Neumora uses current reports on Form 8-K and other filings to communicate material information about its financial condition, capital structure and key pipeline events.
In recent 8-K filings, Neumora has reported quarterly financial results, including details on research and development and general and administrative expenses, net loss and cash, cash equivalents and marketable securities. These filings also reference the company’s expectation that its available capital will fund its operating plan into 2027, based on the specific reporting dates. Other 8-Ks describe business updates such as the initiation of a Phase 1 SAD/MAD study of NMRA-898, a positive preclinical data announcement for NMRA-215, and the associated press releases furnished or filed as exhibits.
Neumora has also filed an 8-K describing a conversion under its Loan and Security Agreement with K2 HealthVentures LLC, in which a portion of the outstanding term loan principal was converted into shares of common stock. This filing outlines the conversion terms, the number of shares issued and the reliance on a registration exemption under the Securities Act of 1933.
On Stock Titan, Neumora’s SEC filings are updated as they appear on EDGAR, and AI-powered summaries help explain the key points in plain language. Users can review current reports on Form 8-K for material events, track changes related to financing arrangements, and connect these disclosures with the company’s broader clinical and business narrative. This page is a resource for understanding how Neumora reports its financial results, capital transactions and significant pipeline milestones to regulators and investors.
ARCH Venture-affiliated funds filed Amendment No. 4 to a Schedule 13D reporting their beneficial ownership in Neumora Therapeutics, Inc. The ARCH funds report beneficial ownership of 33,847,838 shares of Common Stock, representing 18.6% of Neumora’s outstanding shares, based on 182,040,945 shares reported outstanding in the issuer’s recent annual report.
Individual reporting persons include Kristina Burow with 33,965,419 shares deemed beneficially owned (18.7%), reflecting fund interests plus personal holdings, options and restricted stock units, and Steven Gillis with 31,526,272 shares (17.3%). The group states that no reporting person has effected transactions in Neumora’s stock during the last 60 days.
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on brain and centrally mediated diseases, with multiple drug candidates across neuropsychiatric, neurodegenerative and metabolic disorders.
The lead asset, navacaprant, a kappa opioid receptor antagonist for major depressive disorder, is in the KOASTAL Phase 3 program. KOASTAL‑1 did not meet its primary endpoint, and the company optimized and fully enrolled KOASTAL‑2 and KOASTAL‑3, each with more than 400 patients, targeting a joint topline readout in the second quarter of 2026.
NMRA‑511, a V1a receptor antagonist for agitation in Alzheimer’s disease, showed clinically meaningful Phase 1b results, with multiple ascending dose data expected in the second half of 2026 and a Phase 2 trial planned for the first quarter of 2027. NMRA‑898, an M4 positive allosteric modulator for schizophrenia, is in a multiple ascending dose Phase 1 study with data expected in the second half of 2026.
NMRA‑215, a brain‑penetrant NLRP3 inhibitor for obesity, produced up to 19% weight loss as monotherapy and 26% in combination with semaglutide in diet‑induced obesity mouse studies but encountered unexpected findings in a 13‑week rat toxicology study. Neumora is repeating that study and now expects first‑in‑human trials in the first quarter of 2027.
The company also advances preclinical CK1δ and GCase programs for ALS and Parkinson’s disease and reports control of a large intellectual property estate, with over 400 owned, co‑owned, or exclusively licensed patents and applications as of December 31, 2025. The aggregate market value of common stock held by non‑affiliates was approximately $63.3 million as of June 30, 2025, and 182,040,945 common shares were outstanding as of March 23, 2026.
Neumora Therapeutics reported fourth-quarter and full-year 2025 results alongside major pipeline updates. The company recorded a Q4 2025 net loss of $59.4 million and a full-year 2025 net loss of $236.9 million, reflecting continued investment in R&D-led growth.
Research and development expenses were $176.1 million in 2025, down from $200.9 million in 2024, while general and administrative expenses eased to $60.1 million. Neumora ended 2025 with $182.5 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the third quarter of 2027.
Pipeline news included new Phase 1b data for NMRA-511 in Alzheimer’s disease agitation showing effect sizes up to 0.51 on agitation measures, with a Phase 2 study planned for Q1 2027. The KOASTAL-2 and -3 navacaprant studies are fully enrolled with a joint topline readout expected in Q2 2026. Neumora named NMRA-898 its lead M4 program for schizophrenia based on promising Phase 1 data, and highlighted positive obesity data for NMRA-215 while repeating a 13-week rat toxicology study, now targeting clinical entry in Q1 2027.
Neumora Therapeutics, Inc. officer Aurora Daljit Singh reported an open-market sale of 6,165 shares of common stock on February 17, 2026 at an average price of $3.555 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to vesting restricted stock units. After this transaction, Singh directly owned 82,770 common shares.
Neumora Therapeutics President Joshua Pinto reported a Form 4 showing the sale of 5,967 shares of common stock at $3.535 per share on February 17, 2026. According to the footnote, the shares were sold solely to satisfy tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, Pinto directly holds 57,783 shares, and an additional 152,167 shares are held indirectly by Maple DE Holdings LLC.
Neumora Therapeutics, Inc. director and officer Paul L. Berns reported an open-market sale of 9,819 shares of common stock on February 17, 2026. The shares were sold at a weighted average price of $3.5094 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
After the sale, Berns directly owned 7,395,185 shares of common stock. He also had indirect ownership of 133,097 shares held by LULU TRUST OF 2024 for specified beneficiaries, as noted in the footnotes.
Neumora Therapeutics officer Michael Lee Milligan reported an open-market sale of 1,436 shares of common stock at $3.565 per share. The February 17 transaction was executed under a pre-established Rule 10b5-1 trading plan that automatically sells shares on each covered restricted stock unit vesting date to satisfy withholding obligations.
After this sale, Milligan directly held 21,034 Neumora common shares. The filing describes an automated, plan-driven disposition rather than a discretionary trade decision.
Neumora Therapeutics ownership disclosure: Reporting persons led by Invus Public Equities, L.P. state beneficial ownership as of February 13, 2026. Invus Public Equities directly held 8,172,814 shares and Avicenna Life Sci Master Fund directly held 825,008 shares.
The filing shows Raymond Debbane may be deemed beneficial owner of 8,997,822 shares, representing 5.4% based on 167,089,114 shares outstanding as of November 1, 2025, per the issuer's Form 10-Q. The reporting persons certify the holdings were not acquired to change or influence control.
K2 HealthVentures Equity Trust LLC and its managing members Parag Shah and Anup Arora report a 5.01% beneficial ownership stake in Neumora Therapeutics, Inc. common stock as of December 31, 2025. They may be deemed to beneficially own 8,997,035 shares in total.
This consists of 1,055,899 shares held directly by K2 HealthVentures Equity Trust and 7,941,136 additional shares that the trust has the right to acquire within 60 days through conversion of the issuer’s outstanding debt. These conversion rights arise under a Loan and Security Agreement originally dated May 9, 2025 and later amended.
All 8,997,035 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The filers certify the securities were not acquired and are not held for the purpose of changing or influencing control of Neumora Therapeutics.
Neumora Therapeutics, Inc. reported a planned Rule 144 sale of common stock by an affiliated holder. The notice covers 5,967 shares of common stock, with an aggregate market value of $21,093.35, to be sold through Merrill Lynch on NASDAQ around 02/17/2026.
The shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Neumora reports that 167,089,114 shares of common stock were outstanding, providing context for the size of this prospective sale.